(Q40733432)

23 September 2017

A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease (English)

1 reference

multicenter clinical trial

23 September 2017

0 references

0 references

Alzheimer's disease

0 references

author name string

C Y Bae

1

1 reference

23 September 2017

C Y Cho

2

1 reference

23 September 2017

K Cho

3

1 reference

23 September 2017

B Hoon Oh

4

1 reference

23 September 2017

K G Choi

5

1 reference

23 September 2017

H S Lee

6

1 reference

23 September 2017

S P Jung

7

1 reference

23 September 2017

D H Kim

8

1 reference

23 September 2017

S Lee

9

1 reference

23 September 2017

G D Choi

10

1 reference

23 September 2017

H Cho

11

1 reference

23 September 2017

H Lee

12

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 December 2000

1 reference

Journal of the American Geriatrics Society

23 September 2017

1 reference

23 September 2017

48

1 reference

23 September 2017

12

1 reference

23 September 2017

1566-1571

1 reference

A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group

23 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB03865.X

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB03865.X

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB03865.X

Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB03865.X

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB03865.X

Nerve growth factor and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB03865.X

Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB03865.X

Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: short-term study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB03865.X

A multidimensional approach in testing nootropic drug effects (Cerebrolysin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB03865.X

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB03865.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB03865.X

Pathological verification of ischemic score in differentiation of dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB03865.X

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB03865.X

Oral physostigmine treatment of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB03865.X

STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB03865.X

Efficacy of xantinolnicotinate in patients with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB03865.X

10.1111/J.1532-5415.2000.TB03865.X

21 January 2018

Identifiers

DOI

1 reference

23 September 2017

1 reference